Eyeworld

R Contact information Name: by Title OCTOBER 2019 | EYEWORLD | 43 Postoperative expectations Dr. Stephens found that patient responses to the drug eluting plug have been promising. "We do an injection of antibiotic and steroid at the time of cataract surgery and we have them on a combination drop of prednisolone, gatifloxacin, and bromfenac once a day for 2 weeks," he said, adding that so far results have been good. Dr. Berdahl agreed that those already on a steroid antibiotic combination in conjunction with Dextenza won't need much else. The FDA study 1 showed that at day 14 approximately 52% of patients had the absence of anterior cell flare compared with 31% in the placebo group. While there can be some complications, these are limited. With the plug in the eye, patients' tears don't drain as rapidly as they would otherwise. "In an older popula- tion, we like those extra tears around in the healing period with cataract surgery," Dr. Berdahl said. One possibility to watch out for is difficulty getting the plug in all of the way, in which case you might have to trim this postoperatively, Dr. Berdahl noted. Dr. Stephens pointed out that rebound inflammation can sometimes be an issue. However, this has only oc- curred in one of his cases so far and it responded well to topical steroids. "The main thing is telling patients that if they have some inflammation afterward, we might have to give drops for a little bit longer," he said. Another side effect could be increased IOP. "This happened in 6% of eyes in the FDA trial," Dr. Stephens said. "So far we have avoided using this in patients who we were worried about having an IOP spike such as those with glaucoma." If such a spike were to occur, the pres- sure would be treated with topical medication until the plug dissolves at about 1 month or until the pressure goes down, he noted. When it comes to the addition of topical steroids postoperatively, Dr. Stephens has found only 1 out of 30 to 40 patients has needed it. Dr. Berdahl said that Dextenza is a forerunner. "Dextenza is one of the early products to do ocular drug delivery," he said. "If we can get it right, we'll improve results and we'll make it so we're less dependent on patient compliance for good outcomes." Our Charity Delivers High-Volume, Well-Equipped Phacoemulsification Projects to the Impoverished of Mexico. We are Now Recruiting Volunteer Phaco Surgeons for Our Upcoming Surgical Projects in 2020. Learn More About Us and Contact Us at: www.choseneyemission.com Are You a Phaco Surgeon Interested in Compassionate Surgery in the Developing World?

• Blank Page
• Blank Page (1)